Last reviewed · How we verify
NCT05905549
Extended Pancreatic Transection Versus Conventional Pancreatic Transection During Laparoscopic Pancreaticoduodenectomy
trial testing extended pancreatic transection during laparoscopic pancreaticoduodenectomy in Laparoscopic Pancreaticoduodenectomy in 184 participants. Status unknown.
30 December 2023
Quick facts
| Lead sponsor | Xinrui Zhu，MD |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 184 |
| Start date | 1 August 2023 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 June 2024 |
Drugs / interventions tested
- extended pancreatic transection during laparoscopic pancreaticoduodenectomy
Conditions studied
- Laparoscopic Pancreaticoduodenectomy — all drugs for Laparoscopic Pancreaticoduodenectomy →
Sponsor
Xinrui Zhu，MD — full company profile →
Who can join
Adults 18 to 90, any sex, with Laparoscopic Pancreaticoduodenectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The level of pancreatic neck transection during laparoscopic pancreaticoduodenectomy (LPD) is not conclusive. Theoretically, the level of pancreatic transection can significantly affect the occurrence of postoperative pancreatic fistula (POPF) by influencing both the blood supply to the anastomosis and the location of the main pancreatic duct in the pancreatic transverse section. The investigators conduct a retropective propensity score-matched comparison to compare the impact of extended pancreatic transection and conventional pancreatic transection on POPF and the performance of the pancreaticojejunostomy during LPD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05905549
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Xinrui Zhu，MD trials
Trials by the same sponsor.
- NCT06128603 — Analysis of Intraoperative Bleeding Characteristics in Laparoscopic Pancreaticoduodenectomy · unknown
- NCT06172062 — Establishment and Application of an Artificial Intelligence Algorithm for Automatic Identification of Intraoperative Ble · unknown
- NCT04997850 — The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05905549 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xinrui Zhu，MD
- Last refreshed: 18 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05905549.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing